What is Ductal Carcinoma In Situ (DCIS)? | Dana-Farber Cancer Institute
Elizabeth Ann Mittendorf, MD, PhD, director of the Ductal Carcinoma in Situ (DCIS) Program at Dana-Farber, discusses DCIS, including treatment options and opportunities to participate in research. DCIS is the earliest form of breast cancer where the abnormal cells are confined within the milk duct of the breast. DCIS is sometimes referred to as stage 0 cancer, non-invasive breast cancer, or pre-cancer. To learn more about the DCIS Program, visit www.dana-farber.org/ductal-carcinoma-in-situ-program
🎬 More from Dana-Farber Cancer Institute
Understanding Chemo Neuropathy: A Webinar by the Older Adults with GI Cancer Program | Dana-Farber
19 views
Learning About Chronic Lymphocytic Leukemia | Lymph Notes: A Lymphoma Learning Series
112 views
ASCO26: David Reardon, MD Glioblastoma Vaccine | Dana-Farber Cancer Institute
106 views
Society of Gynaecological Oncology Congress 2026: Tara Berman, MD | Dana-Farber Cancer Institute
30 views
ASCO26: Julia Rotow, MD Silevertinib in Lung Cancer | Dana-Farber Cancer Institute
55 views
ASCO26: Atish Choudhury, MD, PhD A-DREAM/Alliance A032101 | Dana-Farber Cancer Institute
38 views